Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Off-Label Debate Between FDA, Industry To Formally Begin After Election

31 Aug 2016

• By Michael Cipriano

FDA entrance sign 2016

Related Content

US FDA Sets Goal For Biosimilar, Drug Promotion Guidances

26 Jan 2016

Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

14 Mar 2016

Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes

27 Jul 2016

Off-Label Communications: BIO Lays Ethical Foundation For Change

09 Aug 2016

Related Companies

Amarin Corp plc

Additional Topics

United States Legal Issues Regulation BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.